However, we were unable to conclusively demonstrate that CBP/p300 inhibition promotes SCLC transformation in conjunction with loss of p53 and RB in EGFR-TKI-treated EGFR-mutant LUAD cells as hypothesized. Here, EP300 is linked to small cell lung carcinoma.